poisar

Stock

Legend Biotech Corporation LEGN

$27.88-0.57%

Overview

LEGN market data

Price History

LEGN price chart

Valuation & Profitability

Twelve Data
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$0.81
Diluted earnings per share over the trailing twelve months.
Beta
0.38
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$16.24 – $45.30
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $4.4K · P/B 3.97 · P/S 3.84.

Company news

10 captured
UBS Downgrades Legend Biotech to Neutral, Lowers Price Target to $28Benzinga · Jul 24, 2026, 11:27 AM
Top 3 Health Care Stocks That May Rocket Higher In JulyBenzinga · Jul 20, 2026, 10:03 AM
JP Morgan Reinstates Neutral on Legend Biotech, Announces $35 Price TargetBenzinga · Jul 13, 2026, 11:01 AM
RBC Capital Maintains Outperform on Legend Biotech, Lowers Price Target to $63Benzinga · Jul 7, 2026, 4:25 PM
Why Is Legend Biotech Stock Falling Thursday?Benzinga · Jun 18, 2026, 1:15 PM
Legend Biotech, Sleep Number And Other Big Stocks Moving Lower In Thursday's Pre-Market SessionBenzinga · Jun 18, 2026, 12:05 PM
Legend Biotech Commences $225M Offering Of Its American Depositary SharesBenzinga · Jun 17, 2026, 8:35 PM
UBS Maintains Buy on Legend Biotech, Raises Price Target to $49Benzinga · Jun 3, 2026, 6:45 PM
Legend Biotech shares are trading higher after the company reported preliminary clinical data for LB2501Benzinga · Jun 2, 2026, 2:32 PM
Legend Biotech Reports 100% Response Rate And 83% Complete Remission Rate In Phase 1 Trial Of LB2501 In Vivo Dual-Targeting CAR-T Therapy For Relapsed/Refractory B-Cell LymphomaBenzinga · Jun 2, 2026, 1:33 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock